Value, Focus, and the Future of MedTech: M&A and Divestitures are Rewriting the Strategic Playbook.

MedTech has entered an era where value, focus, and disciplined portfolio design are no longer optional, they are existential requirements. As global markets tighten and competitive dynamics accelerate, M&A and divestitures have become the primary levers leaders use to reshape their portfolios for market positioning and sustained growth. The most active acquirers are now pursuing access-ready assets, a trend reinforced by recent analyses from Bain & Company, EY Firepower report: Life science dealmaking, McKinsey & Company, and other industry benchmarks.

What has fundamentally changed is the role of Market Access. It has moved from a downstream post-launch consideration to the central input guiding M&A divestitures, and long-term value creation. The industry now recognizes that innovation alone no longer drives valuation; access maturity, evidence strength and clarity of monetization pathways determine enterprise worth.

This shift is rewriting the strategic playbook. Wall Street quarterly earnings from Boston Scientific (Q4-2024) to Intuitive Surgical (Q4-2024) increasingly reference reimbursement, ASP pressures and global pricing headwinds as core determinants of performance. Access has become the lens through which leaders evaluate risk, durability, and the true potential of their portfolios.

In a sector reshaped by divestitures, carve-outs, and targeted acquisitions, the companies that design for access early, build the evidence to sustain it, and protect it over time will lead in multiple categories. This is how MedTech leaders will unlock the full value of innovation for patients, health systems and shareholders.

The Question Facing MedTech Leaders

Industry leadership teams are revisiting foundational questions about where value is created and who is best positioned to unlock it. They are asking, and with increasing urgency:

• Does our access strategy create durable returns, protect valuation, and position this asset for future acquisition or partnership?
• Is this asset truly part of our core portfolio, or could a different owner create more value with it?
• Do we have the investment model, expertise, and scale required to lead in this category?
• Are we designing a Market Access strategy that ensures patients receive greater value in the future, positioning us to thrive in the global health systems of tomorrow?

These questions reflect the core themes identified across M&A, divestiture, spin-off  industry reports. To address them, MedTech leaders are reorganizing portfolios, divesting assets that no longer fit, acquiring access-ready platforms, reshaping category focus to ensure that capital, leadership, and access strategy are aligned to where future value will be created.

The Strategic Reset: Portfolio Value Through a Market Access Lens

Market Access is one of the most powerful determinants of whether a medical technology can deliver sustained revenue, durable margins, and long-term enterprise value. A future ready access strategy now determines valuation, ROI, and acquisition success across the MedTech sector. In quarterly earnings and M&A disclosures, ASP pressure and reimbursement uncertainty are the most frequently cited as primary reasons for portfolio restructuring. Companies are divesting business where pricing pressures erode long-term value, placing them with the next best owner to unlock their full potential.

At the same time, acquirers are concentrating capital on technologies with strong access fundamentals and clear monetization pathways, particularly those that strengthen existing portfolios or pipelines. Recent transactions such as Boston Scientific’s acquisition of Baylis and Silk Road and Abbott’s continued expansion in structural heart all reflect a disciplined focus on access-aligned assets that fit strategically.

Taken together, these trends highlight why portfolio evaluation though a Market Access lens has become essential. Three dimensions now shape the true value and scalability of a product:

• Revenue Probability – the combined impact of reimbursement feasibility and the evidence burden required to secure and maintain coverage, balanced against cost of capital.
• ASP durability – the stability of margin over time, reinforced by global access scalability and the asset’s economic “profit fit” across markets.
• Pipeline Value – the feasibility and strategic importance of indication expansion as a driver of long-term growth and portfolio advantage

Collectively, these elements reveal how value is created and protected and explain why leaders are restructuring portfolios with access at the center:

M&A and Divestitures Examples Where Access Strategy Drove Success

These companies demonstrate that access-readiness now drives the most important strategic moves in MedTech. Guiding portfolio, investment, and ownership decisions.

GE Healthcare: 2023 spin-off

GE Healthcare’s 2023 spin-off established the company as a global leader in precision care, giving it the structural autonomy needed to pursue access-aligned growth at scale. Approved by GE’s Board of Directors in 2022 and completed in January 2023, the separation allowed GE Healthcare to operate as an independent company with a strategy centered on reimbursed diagnostics, predictable recurring revenue, and strong clinical evidence. Categories where access maturity and payer alignment are essential.

The rationale was clear: GE Healthcare could create more value as an independent company with a strategy around reimbursed diagnostic, predictable recurring revenue, strong clinical evidence, and outcomes.

Philips: acquisition of Volcano

Philips Acquisition of Volcano was a deliberate move to position the company as a leader in catheter-based imaging specifically IVUS and FFR, complementing its interventional X-ray and ultrasound portfolio, and expanding its global leadership in Image-guided therapy.

Strategically, Philips bought an access-ready category with established reimbursement, strong provider economics, and global scalability. Enabling it to strengthen procedure economics across cardiovascular interventions. IVUS and FFR already carried clear CPT codes, stable ASPs, and favorable hospital margins, supported by robust clinical and economic evidence that reduce payer friction, and reinforced long-term pricing durability.

By integrating Volcano’s technologies into its imaging portfolio, Philips enhanced procedure value for providers and secured a leadership position in a category defined by durable reimbursement and high clinical relevance.

As Philips leadership emphasized, the acquisition was designed to accelerate the company’s transformation into a comprehensive image-guided therapy leader anchored in evidence, reimbursement stability and global scalability.

Siemens: 2018 decision to spin off Healthineers

Siemens’ 2018 decision to spin off Healthineers created the structural independence needed for the business to scale evidence-intensive modalities and execute globally coordinated access strategies. By separating from the industrial capital constraints of the parent company, Healthineers gained autonomy to pursue market-specific access models across Europe and Asia, investing heavily in MR, CT and molecular imaging, strengthening global pricing discipline, and accelerating its push into precision medicine and digital diagnostics. Areas where mature access governance is essential.

Siemens CEO Roland Busch described the move as “the beginning of the next stage of growth for Siemens,” emphasizing that relinquishing majority control would enable both companies to accelerate value creation in their respective markets. This rationale was highlighted during the investor roadshow, where Siemens leadership stated that “Healthineers needs autonomy to invest in evidence-intensive categories and execute globally coordinated access strategies,” a position widely reflected in reporting from outlets such as Reuters and the Financial Times.

Healthineers CEO Bernd Montag reinforced the strategic intent from the operating side noting in the company’s press release: “We want to take our company to the next level, using our global presence and experience to help our customers increase efficiency, drive clinical excellence and expand healthcare access.”

Boston Scientific: acquisitions of Baylis and Silk Road Medical

Boston Scientific’s acquisitions of Baylis and Silk Road Medical demonstrate the company’s disciplined strategy of acquiring access-ready cardiovascular assets. Categories defined by reimbursement durability, strong provider economics and a clear value proposition.

Baylis strengthened Boston Scientific’s cardiology portfolio through its transeptal access technologies, a critical enabler for left‑heart procedures and a natural complement to the company’s existing electrophysiology and structural heart platforms.

The investor deck emphasized the strategic rationale: commercial and technical synergies that accelerate global growth and strengthen leadership in a fast-growing segment. Successfully positioning the company as a leader in a fast-growing segment.

The acquisition of Silk Road Medical added the TCAR platform, broadening Boston Scientific’s offering for stroke prevention and reinforcing its commitment to minimally invasive vascular innovation, as highlighted by Cat Jennings, president of vascular peripheral interventions.

Reporting across PR Newswire, MedTech Dive, and Medical Device Network underscored that both acquisitions brought categories with stable ASPs, predictable payment structures, and strong clinical and economic evidence.

Together, they positioned Boston Scientific in the minimally invasive cardiovascular space by adding high‑growth, access‑mature platforms where reimbursement clarity and evidence strength translate directly into long‑term value.

Creating Growth by Refocusing: The Rise of the Next Best Owner

One of the most important shifts in MedTech portfolio strategy is the recognition that some businesses can create more value under different leadership, capital allocation, and access strategy. When placed in that environment they often accelerate faster and, in many cases outperform wall street expectations. This is why leaders are increasingly divesting assets where the next-best owner can unlock greater value, while pursuing targeted M&A that strengthens existing portfolios and advances long-term strategic priorities. The result is a deliberate reshaping of portfolios around access-ready categories that can scale globally, sustain ASP durability, and contribute meaningfully to the enterprise value.

Why NewCos Win

NewCos win because they are built for strategic clarity, access readiness, and value creation at scale. They pursue one strategy, design access into the business from day one, move faster through leaner governance, and invest capital where it strengthens evidence, pricing durability and global scalability. Their leadership teams are intentionally matched to the specific business growth needs. In a landscape defined by carve‑outs, portfolio focus, and access‑driven value. NewCos are focused, faster, and structurally advantaged.

Capital Fit: Evidence heavy categories require dedicated investment, capital allocation aligned to evidence generation, access readiness, and global value strategy. Business groups with broad portfolios often struggle to justify sustained investment required to build robust global evidence and value packages. When these assets move to a category focused owner, they finally receive the capital intensity and sequencing needed to scale, accelerate adoption, and unlock product value. A Bain & Company case study shows that a strategic spin-off increased parent company’s value by $500 million.

Access Strategy Fit: A parent company’s access strategy is not always the right access strategy for every category it owns. Many require a specific value narrative, pricing logic, provider economic framing, and global launch sequencing. In a NewCo, the access strategy is built around the business’s needs revealing value and a path forward that were previously constrained. This is where NewCos excel and in doing so they unlock value for shareholders.

Leadership fit: NewCo success depends on leadership that is aligned, accountable and able to make fast, category-specific decisions. As PwC notes its work on portfolio renewal, talent is a strategic differentiator and an advantage especially team with the divestiture experience and organizational fluency to transition products, culture, and operating models effectively. These leaders and teams understand pricing dynamics, market access, global sequencing, and the evidence to access interplay that drives long-term value.

Spin-offs have become a deliberate engine of growth. The post-spin trajectory of Siemens Healthineers, Solventum and GE Healthcare demonstrate what happens when a business is given dedicated leadership, focused capital, and an access strategy built for its category.

Solventum offers a clear example. In its first year as a NewCo, the company exceeded earning expectations, and  company leadership emphasized on Q1 2026 earnings call that performance was driven by “strong execution on growth drivers, strategic portfolio moves, and cost management”. They also noted that they expect to continue building on this momentum and optimize its portfolio for long-term value creation.

GE Healthcare continues to attract new investors while expanding into AI and Digital.And according to MassDevice, Siemens Healthineers now stands as the fourth-largest MedTech company in the world.

These moves reflect a strategic truth: some categories create more value when they operate independently, with governance and investment aligned to their specific growth model.

Access as the Determinant of MedTech Enterprise Value

Today, Market Access is one of the most powerful determinants of MedTech enterprise value. It is a required diligence item, a valuation multiplier, and the strongest predictor of acquisition success. Assets with reimbursement durability, strong provider economics, and evidence-ready global pathway consistently outperform expectations as highlighted on quarterly earnings calls.

As a required diligence item, access reveals whether an asset can truly scale. Helping buyers understand the economic viability, the evidence burden required for global expansion, and whether their own infrastructure can unlock the assets full value.

As a valuation multiplier, access ready assets get higher valuation because they reduce uncertainty and increase confidence in future cash flows. A strong access strategy provides clarity on how the innovation reaches patients, assurance that reimbursement and ASP durability can be sustained, and aligns evidence to global expansion. In a capital-selective environment, access maturity becomes one of the few reliable indicators of premium valuation.

As the predictor of acquisition success, deals succeed when the buyer can immediately integrate the innovation into a proven access infrastructure, enabling rapid scale, evidence acceleration, and ASP protection. Access readiness as the defining factor of post-acquisition performance.

Market Access: The Enterprise Value Engine in M&A and Divestitures

At the center of every successful acquisition, divestiture, or portfolio redesign is a single question: Where does this asset create the most enterprise value and under whose ownership? Market Access is the only function equipped to answer that question with clarity, speed, and system-level precision. Determining which strategic decision create value, where assets can scale and under whose ownership, they will deliver the greatest long-term impact.

For Buyers, Market Access reveals whether an asset’s value story is durable, reimbursable, and globally scalable. The three determinants of whether a technology can accelerate category leadership. In a market where capital is selective and valuations are recalibrating, this insight it decisive. When Market Access leads diligence, buyers double down on assets that can scale.

For Companies Divesting, Market Access defines the restructuring thesis and strengthens the value narrative. It clarifies where a new owner could unlock greater access, adoption, and patient impact. Divestiture become a deliberate reallocation of innovation to the owner best positioned to grow its market share, a strategic act of value creation.

For Startups Preparing for Acquisition, Market Access is now a differentiator that determines whether a buyer sees it as a technology or as a scalable business. A startup with a clear access strategy, evidence plan, and a global expansion pathway become irresistible. Buyers are no longer purchasing technology alone, they are purchasing time to patient access, clarity of value, and predictability of margin.

For R&D, Market Access has moved upstream. It shapes clinical endpoint, evidence strategy, workflow integration, and economic value propositions from the earliest stages of development. Product built with Market access at the table are inherently more resilient achieving global adoption with fewer surprises, fewer delays, and stronger margins that directly influence a company’s valuation.

In reshaping MedTech landscape, the companies that win will be those that treat Market Access not as a support function, but as a core architect of enterprise value.

The post Value, Focus, and the Future of MedTech: M&A and Divestitures are Rewriting the Strategic Playbook. appeared first on MedTech Intelligence.

🔗 Read the full article on the original source